)
Visual
test
Biosergen
Biosergen (BIOSGN) investor relations material
Biosergen Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary10 Feb, 2026
Executive summary
Advanced BSG005 program with focus on manufacturing readiness and regulatory progress, including a successful pre-IND meeting with the FDA providing clear guidance for next steps in clinical development.
Completed second cohort in proof-of-concept trial for BSG005; preparing for next phase and resumption of clinical trials in India.
Strengthened team with appointment of a Global Senior Project Director to support clinical trial execution.
Financial highlights
Operating loss for Q4 2025 was SEK -12.5 million, compared to SEK -2.3 million in Q4 2024, reflecting increased investment in clinical and regulatory activities.
Net loss for Q4 2025 was SEK -12.5 million (SEK -5.31 per share), compared to SEK -2.2 million (SEK -0.95 per share) in Q4 2024.
Cash and cash equivalents at year-end 2025 were SEK 15.4 million, down from SEK 50.6 million at year-end 2024.
Total assets decreased to SEK 21.1 million from SEK 53.0 million year-over-year.
No new share issues or financing inflows in Q4 2025; cash flow from operating activities was SEK -7.8 million.
Outlook and guidance
Priorities for 2026 include completing release of the new BSG005 drug batch, maintaining regulatory interactions, and resuming clinical trials in India.
Company is evaluating financing alternatives to secure resources for continued development amid challenging funding conditions.
BSG005 new batch release timeline
BSG005 development funding plan
BSG005 Nano development next steps
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Biosergen
- BSG005's first patient showed recovery, and Q2 losses narrowed as clinical trials advanced.BIOSGN
Q2 202418 Dec 2025 - Advanced BSG005 development and strong financial position support continued clinical progress.BIOSGNQ3 202518 Dec 2025
- Clinical milestones, improved financials, and strong funding support future growth.BIOSGNQ4 202418 Dec 2025
- BSG005 demonstrated clinical efficacy and safety, with improved Q1 financials and strong cash reserves.BIOSGNQ1 202518 Dec 2025
- Promising BSG005 trial results and improved Q3 financials highlight clinical and operational progress.BIOSGNQ3 202418 Dec 2025
- Clinical progress, leadership changes, and strong cash position mark Q2 2025.BIOSGNQ2 202518 Dec 2025
Next Biosergen earnings date
Q1 202621 May, 2026
Biosergen
Next Biosergen earnings date
Q1 202621 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage